Literature DB >> 8129495

Early diabetic nephropathy. Emerging treatment options.

M J Carella1, V V Gossain, D R Rovner.   

Abstract

Diabetic nephropathy affects approximately 35% of patients with insulin-dependent diabetes mellitus and about 5% to 10% of patients with non-insulin-dependent diabetes mellitus. Diabetic kidney disease can be detected early by special methods that measure microalbuminuria in the range of 15 to 140 micrograms/min or 0.02 to 0.20 g/d. Specific strategies have been proved beneficial in patients with this early diabetic kidney disease, also called "incipient nephropathy." Protein restriction, tight control of blood sugar and blood pressure, and specific therapy with angiotensin-converting enzyme inhibitors have been shown independently to reduce microalbuminuria and preserve renal function in these patients. We review the pathogenesis of diabetic kidney disease and discuss the effects of these treatment strategies on the renal, cardiovascular, metabolic, and other abnormalities found in early (incipient) and overt diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129495

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

Review 1.  Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.

Authors:  Jay Garg; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

2.  Physical activity alters urinary albumin/ creatinine ratio in type 1 diabetic patient.

Authors:  Ercan Tuncel; Erdinc Erturk; Canan Ersoy; Sinem Kiyici; Cevdet Duran; Nesrin Kuru; Sazi Imamoglu
Journal:  J Sports Sci Med       Date:  2004-03-01       Impact factor: 2.988

3.  Early signs of microvascular complications in pediatric patients with short duration of type 1 diabetes mellitus seen in southeast Nigeria.

Authors:  Chinwe Flora Ogugua; Ugo Nnenna Chikani; Maryann Ugochi Ibekwe; Thomas Ngwieri; Holley Allen
Journal:  Ann Afr Med       Date:  2019 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.